Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma

Zijun Xie, Fangyuan Zhou, Yidong Yang, Leijia Li, Ximing Lei, Xianyi Lin, Haijiao Li, Xuemei Pan, Jianning Chen, Genshu Wang, Huiling Liu, Jie Jiang, Bin Wu

ABSTRACT

Background: Long non-coding RNAs (lncRNAs) show great potential as diagnostic tools in many diseases. We aimed to develop sensitive and noninvasive biomarkers in saliva for detecting early hepatocellular carcinoma (HCC).

Methods: Candidate lncRNA biomarkers identified by Agilent microarray were subjected to validation using qPCR for the quantification of their expression levels in independent tissue, plasma and saliva sample sets, including healthy controls and groups of several benign liver diseases and other leading cancers. Its level was significantly reduced after curative hepatectomy but significantly elevated again if HCC recurrence occurred. Salivary lnc-PCDH9-13:1 showed reasonable specificity and sensitivities for detecting HCC compared with several control groups. Furthermore, the overexpression of lnc-PCDH9-13:1 promotes cell proliferation and migration in vitro.

Findings: Lnc-PCDH9-13:1 was significantly elevated in HCC tissues, plasma and saliva of HCC patients compared with healthy controls and groups of several benign liver diseases and other leading cancers. Its level was significantly reduced after curative hepatectomy but significantly elevated again if HCC recurrence occurred. Salivary lnc-PCDH9-13:1 showed reasonable specificity and sensitivities for detecting HCC compared with several control groups. Furthermore, the overexpression of lnc-PCDH9-13:1 promotes cell proliferation and migration in vitro.

Interpretation: Salivary lnc-PCDH9-13:1 is a desirable biomarker for early HCC. It may help warrant prospective validation with larger sample sizes in multi-centers.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Liver cancer, over 90% of which is hepatocellular carcinoma (HCC) categorized by pathology, is the second leading cause of cancer death worldwide in men and the sixth in women, with an overall 5-year survival rate of 5%–9%. An estimated 782,500 new liver cancer cases and 745,500 deaths occurred worldwide during 2012, with China alone accounting for about 50% of the total new cases and deaths [1]. In the USA, incidence rates continue to increase rapidly for liver cancer with 10% per year, leading to HCC in 80% to 90% of individuals [9]. Over 5% of the populations in Asia and sub-Saharan Africa chronically infected with the virus. Accordingly, early diagnosis and surgery are vital for treating HCC.

Studies suggest that long non-coding RNAs (lncRNAs) (≥200 bp) in HCC tissues and blood of patients with HCC show good diagnostic accuracy in detecting HCC [10]. Tissues may secrete lncRNAs into the blood by necrosis and apoptosis. Owing to the extensive blood supply in salivary glands, saliva is considered a terminal product of blood circulation. Saliva may include many components that are derived from blood, because salivary acinar cells produce saliva using blood materials. Hence, saliva can play diagnostic roles in various diseases [11].
We aimed to identify novel and noninvasive lncRNA biomarkers in saliva to help diagnose HCC.

2. Materials and Methods

2.1. Patients and Samples

The study was conducted mainly according to the updated Standards for Reporting of Diagnostic Accuracy (STARD) 2015 reporting guideline for diagnostic accuracy studies [12]. The Healthy controls were defined as individuals with negative results by health examinations, including chest X-rays, oral examinations, abdominal ultrasounds, faecal occult-blood testing, blood cancer biomarker assays (AFP, CEA, CA19-9), HBV antigen, HCV, HIV, and syphilis antibodies. Inactive HBsAg carriers (IHC) had persistent HBV infection of the liver (positive HBsAg over 6 months with serum HBV DNA <10^5 copies/ml) and no laboratory indications of ongoing necroinflammatory hepatic functions; persistently normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations. Chronically hepatitis B (CHB) was defined as chronic necroinflammatory liver function caused by persistent HBV infection (positive HBsAg over 6 months with serum HBV DNA >10^5 copies/ml and persistent or intermittent elevation in AST or ALT concentrations). Patients with liver cirrhosis (LC) were confirmed by biopsy or two imaging modalities (hepatic ultrasound with CT or MRI) [13]. Terminal HCC (Stage IV) was diagnosed based on biopsy of the tumor or CT/MRI [14]. The histopathology results of the patients with the HCC (Stages I, II, III), lung, stomach, colon & rectum, prostate, esophagus, pancreas, leukemia, urinary bladder, non-Hodgkin lymphoma, breast, cervix uteri, ovary cancers, which were 10 leading causes of cancer death in men and women worldwide nowadays [1], were confirmed by pathology after surgical tumor resection or biopsy. Patients with other cancers and benign liver diseases were evaluated with regard to marker specificity. Normal human liver tissues were obtained from distal normal liver tissues of liver hemangioma. The normal liver tissues from liver hemangioma were also determined by pathology. No concurrent oral, infectious, autoimmune diseases and diabetes mellitus were diagnosed in all participants. All HCC patients were positive with HBsAg. Cancer patients with a diagnosis of concurrent two cancers and those undergoing chemotherapy and radiotherapy prior to sample collection were also excluded. Cancer patients were staged according to The American Joint Committee on Cancer: 8th Edition on Cancer Staging [15]. 100 saliva samples was obtained from 50 patients with early HCC over 1 week before and after curative surgery, and saliva from 6 HCC patients among the 50 patients with early HCC was available at the time of documented HCC recurrence with the use of radiographic imaging and, usually, pathological confirmation of recurrence (Fig. 1). Our previous study show adjacent HCC tissues were infiltrated with inflammatory cells, cytokines and cirrhosis [16]. Hence, the majority of adjacent HCC tissues were not “normal” liver tissues. So the levels of lncRNAs in adjacent HCC tissues were not measured and compared since plasma and saliva levels of the candidate lncRNA biomarkers were compared with those of normal healthy controls. The tissue, plasma and saliva samples from all participants were collected consecutively and retrospectively if they met the inclusion criterion between April 2011 and August 2016 at The Third Affiliated Hospital of Sun Yat-sen University.

Institutional review boards or ethics committees from our hospital approved the study protocol. All participants provided written informed consent for their information to be stored in the hospital database and used for research.

2.2. Procedures

Saliva samples were collected as previously described [17]. After the tissue, plasma and saliva samples were collected and stored in the −80 °C lab freezers, the following procedures were finished with seven days. Total RNAs were extracted from frozen liver tissues using TRIzol (Thermo Fisher Scientific, USA), and total RNAs in 1.2 ml of plasma or saliva were isolated by the miRvana PARIS Kit (Thermo Fisher Scientific, USA) according to the manufacturer’s protocols. The lncRNA profiles of the three HCC liver tissues and three normal liver tissues assayed using Agilent Technologies, USA. The measurements of lncRNAs by quantitative polymerase chain reaction (qPCR) were performed as previously described [18]. Each qPCR reaction contained negative controls included no template control, no reverse transcriptase control, and no amplification control. All reactions including controls were carried out in triplicate. Ct values >35 were excluded from the analyses. The expression levels of each lncRNA were normalized to that of β-actin. All expression levels were calculated using the 2^-ΔΔCt method. The indeterminate and missing data were excluded, and qualified samples would be made up the original sample sizes. The expression of candidate lncRNAs in paraffin sections was detected in situ hybridization (ISH) according to the manufacturer’s instructions of the probes (Exiqon, Denmark). The expression of APP in paraffin sections was assayed by immunohistochemistry (IHC) with primary antibody purchased from Gene Company, Hong Kong. Cells with clear brown staining were regarded as positive cells. The APP levels were calculated by enzyme-linked immunosorbent assay (ELISA) with antibody obtained from Cloud-Clone Corp, USA. All experiments were performed at least three times on different days and in triplicate. The sequences of each primer and probe, and detailed
methods of ISH, IHC and ELISA are presented in the Supplementary material.

HCC cell lines, HepG2 and HepG2.2.15 were obtained from the American Type Culture Collection (ATCC, Manassas, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM). Cells were seeded into 96-well plates at a density of 3 \times 10^4 cells per well after transfection. Cell proliferation was examined by the Cell Counting Kit-8 (CCK8) (Dojindo Laboratories, Japan) according to the manufacturer's protocol. The CCK8 optical density (OD) was read at 450 nm for 4 consecutive days. Cell migration was examined using transwell chambers (Corning, USA). The transfected cells at a density of 1 \times 10^5 in 200 μl serum-free medium were seeded to the upper chamber, and DMEM containing 20% fetal bovine serum were added to the bottom chamber. After 24 h, the microscope was used to count the migration cells. The transfected cells were seeded into the 6-well plates at a density of 1 \times 10^6 and grown to reach 90% confluence overnight. Used the 100 μl pipette tip to produce the artificial wound, and washed gently with PBS three times, then cultured in DMEM without FBS. The experiments were photographed with the inverted microscope at 0 and 24 h. ImageJ software (National Institutes of Health, Bethesda, USA) was used to analyze the wound areas.

2.3. Statistical Analysis

LncRNA expression levels were compared using the Mann Whitney U test or Kruskal-Wallis H test. The differences of the lncRNA before and after surgery were studied by Wilcoxon signed-rank test. Receiver operating characteristic (ROC) curves were used to evaluate the discriminatory power of each lncRNA for differentiating between two groups. Optimal cut-off values of the salivary biomarker were determined by the Youden index (Youden index = sensitivity + specificity − 1). When the Youden index reaches the maximum value, the corresponding cut-off value will yield the highest sum of sensitivity and specificity. The correlation between two groups was analyzed using the Spearman’s correlation test. Statistical analyses were performed using the SPSS software (ver. 13.0). A two-tailed P value <0.05 was considered statistically significant.

The experiments and analysis were performed by three investigators working independently. All samples were procured in blinded fashion with regard to which groups they were obtained from. Investigators had no knowledge of the patient’s groups. The experiments were performed in blinded ways, with subsequent data unblinded and analyzed by other co-investigators. All authors ensure the accuracy and completeness of the data and analysis and the fidelity to the technological and biostatistical protocols of this study. No adverse events occurred during performing all the tests.

3. Results

3.1. Patient Characteristics

The characteristics of the study participants are presented in Table 1. There was no significant difference in the distribution of age and sex for the four groups: healthy, inactive HBsAg carrier (IHC), chronic hepatitis B (CHB), liver cirrhosis (LC), early HCC and late HCC. All healthy, IHC, and LC participants showed normal level of serum AFP. But 31 out of 50 (62%) patients with CHB exceeded the normal level. About half of patients with early HCC and terminal HCC showed exceedingly elevated AFP levels, while another half of patients showed normal levels. The tumor sizes of early HCC were <5 cm in greatest dimension with no ≥3 tumors in the livers. Although 12 out of 50 terminal HCC showed smaller 5 cm in tumor size, unfortunately, a major branch of the portal or hepatic vein with direct invasion of adjacent or distal organs were detected by imaging modalities or biopsy.

| Group        | Variable | No. | Group       | Variable | No. |
|--------------|----------|-----|-------------|----------|-----|
| **Healthy**  | Age, years | Mean 55 | **HCC** (I, II) | Age, years | Mean 56 |
| (n = 50)     | SD 10    |     | (n = 50)    | SD 11    |     |
| Sex          | Male     | 25  | Sex         | Male     | 25  |
|              | Female   | 25  | Female      | Female   | 25  |
| Serum AFP   | <20 ng/ml | 50  | Serum AFP   | <20 ng/ml | 16  |
|              | ≥20 ng/ml | 0   | ≥20 ng/ml    | ≥20 ng/ml | 34  |
| **IHC**      | Age, years | Mean 49 | **CHB**     | Age, years | Mean 56 |
| (n = 50)     | SD 13    |     | (n = 50)    | SD 12    |     |
| Sex          | Male     | 25  | Sex         | Male     | 25  |
|              | Female   | 25  | Female      | Female   | 25  |
| Serum AFP   | <20 ng/ml | 11  | Serum AFP   | <20 ng/ml | 25  |
|              | ≥20 ng/ml | 29  | ≥20 ng/ml    | ≥20 ng/ml | 13  |
| **CHB**      | Age, years | Mean 46 | **HCC**      | Age, years | Mean 56 |
| (n = 50)     | SD 10    |     | (n = 50)    | SD 12    |     |
| Serum AFP   | <20 ng/ml | 50  | Serum AFP   | <20 ng/ml | 18  |
|              | ≥20 ng/ml | 0   | ≥20 ng/ml    | ≥20 ng/ml | 28  |
| **LC**       | Age, years | Mean 49 | Tumor size  | III      | 16  |
| (n = 50)     | SD 11    |     | <5 cm       | IV       | 34  |
| Sex          | Male     | 25  | >5 cm       | 12       |
|              | Female   | 25  |             | 38       |
| Serum AFP   | <20 ng/ml | 50  | HBV DNA     | 13       |
|              | ≥20 ng/ml | 0   | Not detected | 18       |

Abbreviations: AFP, alpha fetoprotein; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; IHC, inactive HBsAg carrier; LC, liver cirrhosis; SD, standard deviation.

3.2. The Selection of Candidate lncRNA Biomarkers for HCC

Microarray results showed that numerous lncRNAs were dysregulated in HCC tissues (Fig. 2a). The raw data of the microarray results and the detailed methods of the microarray can be downloaded in Gene Expression Omnibus (Access number GSE98269). According to the bioinformatic analysis of lncRNA-gene network, Inc-PCHD9-13:1 (Current NCBI gene ID: LINCO0355), Inc-GGT1-6:1 (NCBI ID: EST 0000470591), Inc-ARRDC3-1:16 (NCBI ID: LUCAT1) played a pivotal role in HCC development with dozens of cancer genes (Fig. 2b). And no studies have reported they were also dysregulated in other cancers. Accordingly, those lncRNAs were selected as candidate biomarkers for HCC (Fig. 2c). Next, the expression levels of these three lncRNAs were measured by qPCR. 10 HCC tissue samples, plasma samples and saliva sample were from the same 10 HCC patients. Compared with normal liver tissues, Inc-PCHD9-13:1, Inc-GGT1-6:1, Inc-ARRDC3-1:16 were significantly upregulated in HCC tissues according to the qPCR results (Fig. 3a). The deregulation patterns of these candidate biomarkers were consistent with those from microarray results. Compared with healthy controls, Inc-PCHD9-13:1 was significantly elevated in plasma (Fig. 3b) and saliva of HCC patients (Fig. 3c), but Inc-GGT1-6:1, Inc-ARRDC3-1:16 showed no significant differences between the two groups. Hence, Inc-PCHD9-13:1 was chosen as potential salivary biomarkers and measured further in other cohorts with larger sample sizes.
3.3. The Validation of Candidate lncRNA Biomarkers

Immunohistochemical results showed that α-fetoprotein (AFP) expressed in very low levels in normal liver tissues, liver tissue with chronic hepatitis B, liver cirrhosis, and HCC tissues with serum AFP <20 ng/ml. AFP was in mild positive levels in HCC tissues of patients with serum AFP = 20–400 ng/ml and was in strong positive levels in HCC tissues with AFP >400 ng/ml (Fig. 4a). Additionally, by the ELISA results, significant correlation was observed in early HCC, late HCC, and total HCC cases between saliva AFP and serum AFP (Fig. 4b). These results demonstrated that AFP expression in HCC tissue is consistent with serum and saliva AFP levels of the same patients. The results of in situ hybridization results showed that Inc-PCDH9-13:1 (Fig. 5a) was expressed in low levels in normal liver tissues, liver tissue with chronic hepatitis B and liver cirrhosis, but significantly higher in 3 types of HCC tissues, categorized by three groups of serum AFP levels (<20 ng/ml, 20–400 ng/ml, >400 ng/ml). Additionally, the mRNA expression of the reference gene β-actin was also detected by ISH as comparison. The results were presented in Fig. S1. As shown in the figure, the positive signals both RNAs looked similar, so it indicated that the signals were convincing. The results of agarose gel electrophoresis (Fig. 5b) and sequencing (Fig. 5c) demonstrated that the expression levels of Inc-PCDH9-13:1 in tissue, plasma and saliva could be readily and specifically detected by qPCR. Compared with healthy controls, inactive HBsAg carriers (IHC), chronic hepatitis B (CHB), and liver cirrhosis (LC), salivary Inc-PCDH9-13:1 was significantly elevated in early (Stages I & II), terminal (Stages III & IV) and total cases of HCC patients. Salivary Inc-PCDH9-13:1 was also significantly overexpressed in HCC when healthy individuals, inactive HBsAg carriers, patients with chronic hepatitis B (CHB), and liver cirrhosis (LC) were chosen as control groups, respectively (Fig. 6a). Salivary Inc-PCDH9-13:1 was significantly reduced after curative operation, but significantly increased again after HCC recurrence (Fig. 6b). 10 HCC tissue, 10 plasma and 10 saliva samples were procured from the same 10 HCC patients. Spearman’s correlation tests suggested that levels of Inc-PCDH9-13:1 in tissue correlated significantly with those in plasma and saliva (Fig. 6c).
3.4. The Diagnostic Performances of the Salivary IncRNA Biomarkers for HCC

In order to evaluate the marker specificities, salivary levels of Inc-PCDH9-13:1 in patients of 10 leading causes of cancer death excluding HCC in men and women worldwide nowadays were also measured. According to global cancer statistics,10 leading causes of cancer death in men were lung, liver, stomach, colon, prostate, esophagus, pancreas, leukemia, urinary bladder, non-Hodgkin lymphoma. And 10 leading causes of cancer death in women were breast, lung, colon, cervix uteri, stomach, liver, pancreas, ovary, esophagus, leukemia. The results suggested that salivary Inc-PCDH9-13:1 in healthy controls was similar to those in patients of 10 leading causes of cancer death in men and women excluding HCC (Fig. 7a). Through the analysis of ROC curves, salivary Inc-PCDH9-13:1 could detect HCC with sensitivities and specificities of over 85% compared with different control groups (Fig. 7b). ROC curves also indicated that salivary Inc-PCDH9-13:1 showed over 80% of sensitivities and specificities for detecting HCC with different serum AFP levels (Fig. 7c). Taken together, salivary Inc-PCDH9-13:1 showed a better diagnostic value than that of serum AFP.

3.5. Overexpressed Inc-PCDH9-13:1 Promoted Cell Proliferation and Migration In Vitro

The HepG2 and HepG2.2.15 cells were transfected with Inc-PCDH9-13:1 lentiviruses to develop stably over-expressed cell lines of Inc-PCDH9-13:1 (Fig. S2A). To primarily investigate the functions of Inc-PCDH9-13:1 in hepatocarcinogenesis, we observed its role in cell proliferation and migration. The CCK8 assay showed that Inc-PCDH9-13:1 overexpression remarkably promoted cell proliferation ability compared with the vector group in HCC cells (Fig. S2A). In the wound healing

---

Fig. 3. The differential expression levels of candidate lncRNA biomarkers in liver tissue, plasma and saliva. (a) Compared with normal liver tissues, Inc-PCDH9-13:1, Inc-GGT1-6:1, Inc-ARRD3-1:16 were significantly upregulated in HCC tissues. (b) Compared with healthy controls, Inc-PCDH9-13:1 were significantly elevated in plasma of HCC patients, but Inc-GGT1-6:1, Inc-ARRD3-1:16 showed no significant differences between the two groups. (c) Salivary Inc-PCDH9-13:1 was significantly overexpressed in HCC patients, while the other two lncRNAs did not differ significantly between the two groups.
assay, similar results were observed, and higher potential in wound healing was possessed in the HepG2 and HepG2.2.15 cells with overexpressed lnc-PCDH9-13:1 (Fig. S2E, F).

4. Discussion

To the best of our knowledge, this study primarily reports that salivary lncRNAs can serve as biomarkers in the diagnosis of early and AFP-negative HCC, and outperform serum AFP. This study suggested that the aberrant expression of salivary lnc-PCDH9-13:1 might aid in determining the diagnosis and prognosis of HCC. Bioinformatic analysis showed that lnc-PCDH9-13:1 played significant roles with dozens of cancer genes in HCC development. lnc-PCDH9-13:1 were overexpressed in HCC tissue and plasma and saliva of HCC patients, and its levels in tissue correlated significantly with those in plasma and saliva. Sequencing results demonstrated that qPCR could readily and specifically detect the salivary lnc-PCDH9-13:1. It is not aberrantly expressed in some benign liver diseases and other nine leading causes of cancer death. So the specificities and sensitivities of salivary lnc-PCDH9-13:1 in detecting HCC may superior to the current well-established biomarker of HCC, AFP. Elevated lnc-PCDH9-13:1 in saliva could be found in patients with early HCC, and the similarity of lnc-PCDH9-13:1 levels in early- and late-stage HCC indicated that their aberrant expression might be associated with early events in HCC development. Additionally, upregulated salivary lnc-PCDH9-13:1 appeared to reflect the HCC recurrence. Last but not least, functional experiments of lnc-PCDH9-13:1 in vitro suggested that overexpressed lnc-PCDH9-13:1 promoted proliferation and migration. Collectively, salivary lnc-PCDH9-13:1 may be predominantly derived from HCC and selectively released to the bloodstream and saliva, and it may play a role in hepatocarcinogenesis.

Although Alpha-fetoprotein-L3 (AFP-L3) and Des-γ-decarboxyprothrombin (DCP) were reported to be promising biomarkers for HCC, heir diagnostic accuracy remains controversial, and has yet translated into clinical utility. AFP is still the only well-
Fig. 5. Validation of candidate lncRNA biomarker. (a) In situ hybridization results showed that lnc-PCDH9-13:1 was expressed in low levels in normal, hepatitis and cirrhotic liver tissues, but significantly higher in 3 types of HCC tissues, categorized by serum AFP levels. Agarose gel electrophoresis (b) and sequencing results (c) demonstrated that in tissue, plasma, and saliva were readily and specifically detected by qPCR. Clear brown staining was regarded as positive cells.
established biomarker for HCC in clinical practice [19]. However, serum AFP levels are elevated in benign liver diseases, such as hepatitis and cirrhosis. Hence, investigation of Inc-PCDH9-13:1 expression could outperform AFP in terms of helping diagnosing early-stage HCC, AFP-negative HCC and prognostic indicators. Salivary Inc-PCDH9-13:1 is a promising non-invasive and desirable biomarker for HCC. Interestingly, this study also indicated that significant correlation was observed among tissue, serum and saliva AFP. A previous study also reported strong correlation between saliva and serum AFP [5]. Hence, HCC may secret AFP into saliva by blood circulation. But the normal range of salivary AFP for healthy persons has yet determined due to lack large-scale studies.

Saliva as a multi-constituent oral fluid consists of secretions from the major and minor salivary glands, extensively supplied by blood. Molecules such as DNAs, RNAs, proteins, found in blood, could be also found in saliva. Thus, saliva is considered to be a terminal product of bloodstream. LncRNA is emerging as new regulators of diverse physiological functions. Importantly, the differential expression of lncRNAs, together with other molecular defects, plays a significant role in oncogenesis and tumor development. A study [20] reported that lncRNAs could remain stable through they were treated with freeze-thaw cycles, low/high pH, strong acid, strong base, high temperature and RNase A. Thus, lncRNAs are very attractive for the development of new target therapies and appear to be significant for the discovery of new disease-specific diagnostic makers in bodily fluids, including saliva.

The term “salivaomics” was created to highlight the omics constituents in saliva that can be used for biomarker development and personalized medicine. Numerous molecules isolated from saliva have been proposed as disease biomarkers for diagnosis, prognosis, drug monitoring and pharmacogenetic studies [21].

![Fig. 6. The differential expression of salivary Inc-PCDH9-13:1.](image)

(a) Compared with healthy controls, inactive HBsAg carriers, chronic hepatitis B, and HBV-induced liver cirrhosis, salivary Inc-PCDH9-13:1 was significantly elevated in early, late, and total cases of HCC. (b) Salivary Inc-PCDH9-13:1 was significantly reduced after curative operation, but significantly increased after HCC recurrence. (c) According to the Spearman’s correlation tests, the expression of Inc-PCDH9-13:1 in HCC tissue, plasma, and saliva of HCC patients correlated significantly with each other.
Fig. 7. The diagnostic performance of salivary lnc-PCDH9-13:1. (a) Compared with healthy controls, salivary lnc-PCDH9-13:1 did not show significant differences with 10 leading causes of cancer death in men and women excluding HCC, but significantly overexpressed in HCC. (b) Through the analysis of ROC curves, salivary lnc-PCDH9-13:1 could detect HCC with sensitivities and specificities of over 85% compared with different control groups. (c) ROC curves indicated that salivary lnc-PCDH9-13:1 showed over 80% of sensitivities and specificities for detecting HCC with different serum AFP levels.
into the blood circulation by tumor cells undergoing apoptosis or necrosis. Serum, plasma and saliva biomarkers were showed good agreement in several studies, such as C-reactive protein (CRP), interleukin (IL)–6 [22], HIV antibody [23], microRNAs [24, 25], prostate specific antigen (PSA) [26], etc. One development and application of salivary diagnosis is the marketing of FDA-approved testing kits for AIDS, which has been widely used worldwide to screen patients with HIV infection. Oncogenic mutation of some genes could also be detected in plasma and saliva samples [27, 28]. Thus salivaoxics is one of liquid biopsies, which examine physiological biofluids and performs analysis on them for improving cancer management. Notably, not 100% of the released RNAs in vitro and in vivo reflect the cellular or tussular profile. Pigati et al. reported that secreted RNAs did not necessarily reflect the abundance of RNAs in the cell of origin. Some diagnostic RNAs are selectively retained in HCC, while lnc-PCDH9-13:1 was selectively released by HCC.

In vitro and in vivo reagents assists.

In conclusion, salivary lnc-PCDH9-13:1 is a novel hypersensitive and specific biomarker in diagnosis of early HCC. It may help screen for HCC and to diagnose diseases at an early stage. This study was a phase one cancer biomarker study conducted at a single institution, and the number of participants studied was small. For these reasons, replication of our findings in a larger, multi-center, prospectively studied cohort is needed before those two potential saliva biomarkers are used in clinical practice. Future studies should also investigate why lnc-PCDH9-13:1 was selectively overexpressed in HCC tissue, plasma and saliva of HCC patients, and should address the functions in HCC development.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.06.026.

Acknowledgments

We would like to thank all the participants in this study. We would also like to thank Prof. Ziqing Hei, Mian Ge, Department of Anesthesiology; Prof. Renbin Liu, Department of Thyroid and Breast Surgery; Prof. Xiangyuan Wu, Department of Oncology; Prof. Ruiyun Xu, Department of Hepatic Surgery; Prof. Jiajun Liu, Department of Hematology; Prof. Yuqi Zhou; Department of Respiratory Medicine; Dr. Minjuan Ye, Department of Gynaecology; Dr. Qinxiong Huang, Department of Urological Surgery, Dr. Yuhang Pan, Department of Pathology, the Third Affiliated Hospital, Sun Yat-sen University, who provided samples for our studies. We also thank Hanqi Yin (PhD) from Guangdong Longsee Medical Corporation, Shanghai Biotechnology Corporation, Bersinbio Corporation and Guangzhou Sagene Biotech Co., LTD for technical, biostatistical, and bioinformatics assistance.

Funding

This study was supported by National Natural Science Foundation of China (U1501224), the Science and Technology Developmental Special Foundation of Guangdong Province (2017B020226003), the Guangzhou City Science and Technology Program (201604020118), and the Projects of Guangzhou City Health Care Collaborative Innovation (201604020002).

Declaration of Interests

We declare no competing interests.

Author Contributions

Study concept and design: Zijun Xie, Bin Wu. Performing the experiments: Zijun Xie, Fangyuan Zhou, Yidong Yang, Huiying Liu, Jie Jiang, Leijia Li, Recruiting Patients and colleting specimens: Yiming Lei, Xianyi Lin, Haijiao Li,Xuejia Pan, Jiangning Chen, Genshu Wang. Statistical analysis: Zijun Xie, Yidong Yang, Huiying Liu, Bin Wu. Drafting of the manuscript: Zijun Xie, Yidong Yang, Huiying Liu, Bin Wu. Revising of the manuscript: Zijun Xie, Bin Wu.

References

[1] Torre LA, Wang XL, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87–108.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.
[3] Ali R, Barnes I, Cairns BJ, et al. Incidence of gastrointestinal cancers by ethnic group in England, 2001–2007. Gut 2013;62(12):1692–703.
[4] Poon RT, Fan ST. Hepatocarcinoma for hepato cellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004;10(2 Suppl 1):S39–45.
[5] You XJ, Jiang J, Yin FZ. Preliminary observation on human saliva alpha-lactoprotein in patients with hepatocellular carcinoma. Chin Med J (Engl) 1993;106(3):179–82.
[6] Yuen MF, Cheng CC, Laufer IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31(2):330–5.
[7] Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97–107.
[8] Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J (Engl) 2007;120(24):2157–8.
[9] Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015;7(11):1541–52.
[10] Chauhan R, Lahiri N. Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer 2016;8(Suppl 1):S7–55.
[11] Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Med Oncol 2017;34(7).
[12] Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326(7379):41–4.
[13] Shihia G, Sarin SK, Ibrahim AE, et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3(2):323–33.
[14] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020–2.
[15] Kamarajah SK, Frankel TL, Sonnenday C, et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol 2017;117(4):444–50.
[16] Yang Y, Guo Y, Tan S, et al. Beta-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nat Commun 2015;6:7369.
[17] Xie Z, Yin X, Gong B, et al. Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev Res (Phila) 2015;8(2):165–73.
[18] Xie Z, Chen X, Li J, et al. Salivary HO1/HIF1A and PTN as novel biomarkers for early pancreatic cancer. Oncotarget 2016;7(11):25408–19.
[19] Li D, Satomura S, Biomarkers for hepatocellular carcinoma (HCC): an update. Adv Exp Med Biol 2015;867:179–93.
[20] Tong YS, Wang XW, Zhou XL, et al. Identification of the long non-coding RNA POU5F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer 2015;14:3.
[21] Wong DT. Salivacoamps. J Am Dent Assoc 2012;143(10 Suppl):195–245.
[22] Dekker RL, Levine TA, Moser DK, et al. Salivary biomarkers, oral inflammation, and functional status in patients with heart failure. Biol Res Nurs 2017;19(2):153–61.
[23] Fransen K, Vermeulen T, Beeaert G, et al. Using conventional HIV tests on oral fluid. J Virol Methods 2013;194(1–2):46–51.
[24] Humeau M, Vignolle-Vidoni A, Sicard F. Salivary microRNA in pancreatic cancer patients. PLoS One 2015;10(6):e130996.

[25] Sazanov AA, Kiselyova EV, Zakharenko AA, et al. Plasma and saliva miR-21 expression in colorectal cancer patients. J Appl Genet 2017;58(2):231–7.

[26] Shiiki N, Tokuyama S, Sato C, et al. Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma. Biomarkers 2011;16(6):498–503.

[27] Tu M, Chia D, Wei F, et al. Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). Analyst 2016;141(2):393–402.

[28] Wei F, Lin, et al. Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med 2014;190(1):1117–26.

[29] Pigati L, Yaddanapudi SC, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5(10):e13515.

[30] Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007;4(7):424–32.